CDTConduit Pharmaceuticals
About Conduit Pharmaceuticals
Conduit Pharmaceuticals (NASDAQ:CDT) is a clinical-stage biopharmaceutical company focusing on developing drugs for unmet medical needs. They prioritize assets overlooked by larger companies. Their pipeline includes a drug in Phase II for autoimmune diseases and a potential treatment for male infertility. The company is headquartered in San Diego, California.
What is CDT known for?
Snapshot
Public US
Ownership
2019
Year founded
4
Employees
San Diego, United States
Head office
1 of 294
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Conduit Pharmaceuticals
- Drug Development: Conduit identifies promising drug candidates with the potential to address unmet medical needs.
- Clinical Trials: They design and conduct clinical trials to test the safety and efficacy of their drug candidates.
- Partnerships: Conduit may collaborate with other pharmaceutical companies to develop and commercialize their drugs.
- Autoimmune Disease Treatments: Their current pipeline prioritizes drugs for autoimmune diseases like uveitis and Hashimoto's Thyroiditis.
- Male Infertility Treatment: They're also exploring treatments for idiopathic male infertility.
- Licensing: Conduit might license their developed drugs to other companies for further development or commercialization.
Conduit Pharmaceuticals executive team
- Dr. Andrew ReganFounder, CEO & Director
- Mr. James BlighCo-Founder, CFO & Director
- Dr. Joanne M. HollandChief Scientific Officer